RESUMEN
Invasive fungal infections (IFI) pose a significant health burden, leading to high morbidity, mortality, and treatment costs. This study aims to develop and characterize nanomicelles for the codelivery of posaconazole and hemp seed oil for IFI via the oral route. The nanomicelles were prepared using a nanoprecipitation method and optimized through the Box Behnken design. The optimized nanomicelles resulted in satisfactory results for zeta potential, size, PDI, entrapment efficiency, TEM, and stability studies. FTIR and DSC results confirm the compatibility and amorphous state of the prepared nanomicelles. Confocal laser scanning microscopy showed that the optimized nanomicelles penetrated the tissue more deeply (44.9µm) than the suspension (25µm). The drug-loaded nanomicelles exhibited sustained cumulative drug release of 95.48 ± 3.27% for 24 h. The nanomicelles showed significant inhibition against Aspergillus niger and Candida albicans (22.4 ± 0.21 and 32.2 ± 0.46 mm, respectively). The pharmacokinetic study on Wistar rats exhibited a 1.8-fold increase in relative bioavailability for the nanomicelles compared to the suspension. These results confirm their therapeutic efficacy and lay the groundwork for future research and clinical applications, providing a promising synergistic antifungal nanomicelles approach for treating IFIs.
Asunto(s)
Antifúngicos , Aceites de Plantas , Animales , Antifúngicos/administración & dosificación , Antifúngicos/farmacocinética , Antifúngicos/farmacología , Antifúngicos/química , Ratas , Aceites de Plantas/química , Aceites de Plantas/farmacología , Aceites de Plantas/administración & dosificación , Triazoles/administración & dosificación , Triazoles/farmacocinética , Triazoles/química , Triazoles/farmacología , Nanopartículas/química , Ratas Wistar , Candida albicans/efectos de los fármacos , Infecciones Fúngicas Invasoras/tratamiento farmacológico , Aspergillus niger/efectos de los fármacos , Micelas , Semillas/química , Liberación de Fármacos , Masculino , Portadores de Fármacos/químicaRESUMEN
Microparticles as a multicompartment drug delivery system are beneficial for poorly soluble drugs. Mucoadhesive polymers applied in microparticle technology prolong the contact of the drug with the mucosa surface enhancing drug bioavailability and extending drug activity. Sodium alginate (ALG) and hydroxypropyl methylcellulose (hypromellose, HPMC) are polymers of a natural or semi-synthetic origin, respectively. They are characterized by mucoadhesive properties and are applied in microparticle technology. Spray drying is a technology employed in microparticle preparation, consisting of the atomization of liquid in a stream of gas. In this study, the pharmaceutical properties of spray-dried ALG/HPMC microparticles with posaconazole were compared with the properties of physical mixtures of powders with equal qualitative and quantitative compositions. Posaconazole (POS) as a relatively novel antifungal was utilized as a model poorly water-soluble drug, and hard gelatin capsules were applied as a reservoir for designed formulations. A release study in 0.1 M HCl showed significantly prolonged POS release from microparticles compared to a mixture of powders. Such a relationship was not followed in simulated vaginal fluid (SVF). Microparticles were also characterized by stronger mucoadhesive properties, an increased swelling ratio, and prolonged residence time compared to physical mixtures of powders. The obtained results indicated that the pharmaceutical properties of hard gelatin capsules filled with microparticles were significantly different from hard gelatin capsules with mixtures of powders.
Asunto(s)
Alginatos , Cápsulas , Sistemas de Liberación de Medicamentos , Gelatina , Derivados de la Hipromelosa , Triazoles , Alginatos/química , Gelatina/química , Derivados de la Hipromelosa/química , Sistemas de Liberación de Medicamentos/métodos , Triazoles/química , Triazoles/administración & dosificación , Triazoles/farmacocinética , Liberación de Fármacos , Preparaciones de Acción Retardada/química , Antifúngicos/administración & dosificación , Antifúngicos/química , Antifúngicos/farmacocinética , MicroesferasRESUMEN
Invasive fungal infections (IFIs) are growing in importance in veterinary and human medicine. IFIs such as aspergillosis, blastomycosis, coccidioidomycosis and histoplasmosis remain challenging to treat in dogs. Isavuconazole is a novel antifungal medication that, when compared to currently used azoles, has an expanded spectrum of antifungal activity Rudramurthy (2011), Pfaller (2013), Spec (2018), has more predictable pharmacokinetics in humans Desai (2016), Cojutti (2021) and may cause fewer side effects such as liver and renal toxicity Maertens (2016), DiPippo (2018). The pharmacokinetic profile and safety of isavuconazole in dogs has not yet been characterized. The purpose of this study was to evaluate the pharmacokinetics of isavuconazole in healthy dogs that received a single dose of the prodrug isavuconazonium sulfate. Using full crossover design, six healthy beagle dogs received isavuconazonium sulfate at a mean (+/- SD) dose of 20.6 (+/- 2.8) mg/kg orally and 21.8 (+/- 4.2) mg/kg intravenously. Plasma was collected for batched pharmacokinetic analysis of prodrug and metabolite, isavuconazole, by ultra-high-pressure liquid chromatography tandem mass spectrometry (UHPLC-MS/MS). The median (Q1-Q3) maximum isavuconazole peak plasma concentration was estimated at 3,876.5 (2,811.0-4,800.0) ng/mL following oral administration, with a median (Q1-Q3) peak level at 1.3 (1.0-2.0) hours. Following intravenous administration, the median (Q1-Q3) isavuconazole peak plasma concentration was estimated at 3,221.5 (2,241.5-3,609.0) ng/mL, with a median (Q1-Q3) peak level at 0.4 (0.3-0.6) hours. The median (Q1-Q3) half-life of isavuconazole was 9.4 (7.0-12.2) hours and 14.0 (8.1-21.7) hours for oral and intravenous routes, respectively. One dog received inadvertent subcutaneous drug administration without any apparent adverse effects. Another dog experienced an anaphylactic reaction following accidental rapid drug infusion. No other drug-related adverse events were observed. At dosages used in this study, healthy dogs achieved isavuconazole plasma levels comparable to human therapeutic targets, and when properly administered the drug was well-tolerated.
Asunto(s)
Antifúngicos , Nitrilos , Piridinas , Triazoles , Animales , Perros , Piridinas/farmacocinética , Piridinas/administración & dosificación , Nitrilos/farmacocinética , Triazoles/farmacocinética , Triazoles/administración & dosificación , Antifúngicos/farmacocinética , Masculino , Femenino , Administración Oral , Profármacos/farmacocinética , Estudios CruzadosRESUMEN
BACKGROUND: Posaconazole is used for the prophylaxis and treatment of invasive fungal infections in critically ill patients. Standard dosing was shown to result in adequate attainment of the prophylaxis Cmin target (0.7â mg/L) but not of the treatment Cmin target (1.0â mg/L). OBJECTIVES: To provide an optimized posaconazole dosing regimen for IV treatment of patients with invasive pulmonary aspergillosis in the ICU. METHODS: A population pharmacokinetics (popPK) model was developed using data from the POSA-FLU PK substudy (NCT03378479). Monte Carlo simulations were performed to assess treatment Cmin and AUC0-24 PTA. PTA ≥90% was deemed clinically acceptable. PopPK modelling and simulation were performed using NONMEM 7.5. RESULTS: Thirty-one patients with intensive PK sampling were included in the PK substudy, contributing 532 posaconazole plasma concentrations. The popPK of IV posaconazole was best described by a two-compartment model with linear elimination. Interindividual variability was estimated on clearance and volume of distribution in central and peripheral compartments. Posaconazole peripheral volume of distribution increased with bodyweight. An optimized loading regimen of 300â mg q12h and 300â mg q8h in the first two treatment days achieved acceptable PTA by Day 3 in patients <100â kg and ≥100â kg, respectively. A maintenance regimen of 400â mg q24h ensured ≥90% Cmin PTA, whereas the standard 300â mg q24h was sufficient to achieve the AUC0-24 target throughout 14â days, irrespective of bodyweight. CONCLUSIONS: We have defined a convenient, optimized IV posaconazole dosing regimen that was predicted to attain the treatment target in critically ill patients with invasive aspergillosis.
Asunto(s)
Antifúngicos , Enfermedad Crítica , Aspergilosis Pulmonar Invasiva , Método de Montecarlo , Triazoles , Humanos , Aspergilosis Pulmonar Invasiva/tratamiento farmacológico , Triazoles/farmacocinética , Triazoles/administración & dosificación , Antifúngicos/farmacocinética , Antifúngicos/administración & dosificación , Femenino , Persona de Mediana Edad , Masculino , Anciano , Adulto , Administración Intravenosa , Simulación por Computador , Unidades de Cuidados IntensivosRESUMEN
Carboxyamidotriazole (CAI) was previously recognized as a well-tolerated anticancer drug. It has also demonstrated significant anti-inflammatory effects in various cell and animal model experiments, prompting its investigation as a potential treatment for rheumatoid arthritis. In this study, the potential biotransformation metabolites of CAI were identified both in vitro and in vivo. A sensitive, specific, and accurate LC-MS method was developed for the quantitative analysis of CAI and its major metabolite, CAI-OH, in rat plasma. CAI, CAI-OH, and telmisartan (used as an internal standard) were separated using a Zorbax SB C18 column. The mobile phase consisted of water (phase A, containing 0.1% formic acid) and acetonitrile (phase B, containing 0.1% formic acid) at a flow rate of 0.2 mL/min. The analytes were examined using a high-resolution mass spectrometer, with detected mass-to-charge ratios of m/z 424.01293 for CAI, m/z 440.00785 for CAI-OH, and m/z 515.24415 for telmisartan. Good linearity was observed within the range of 10-5000 ng/mL. Both inter- and intra-batch precision (relative standard deviation, %) were below 6%, and the accuracy ranged from 94.9% to 106.1%. The analytes remained stable throughout the entire experimental period. This method was successfully applied in a pharmacokinetic study of CAI following oral administration in rats.
Asunto(s)
Espectrometría de Masas , Ratas Sprague-Dawley , Triazoles , Animales , Ratas , Triazoles/sangre , Triazoles/farmacocinética , Triazoles/química , Masculino , Reproducibilidad de los Resultados , Cromatografía Liquida/métodos , Espectrometría de Masas/métodos , Modelos Lineales , Antirreumáticos/sangre , Antirreumáticos/farmacocinética , Límite de Detección , Sensibilidad y Especificidad , Cromatografía Líquida con Espectrometría de MasasRESUMEN
A significant challenge in the traditional human health risk assessment of agrochemicals is the uncertainty in quantifying the interspecies differences between animal models and humans. To work toward a more accurate and animal-free risk determination, new approaches such as physiologically based kinetic (PBK) modeling have been used to perform dosimetry extrapolation from animals to humans. However, the regulatory use and acceptance of PBK modeling is limited for chemicals that lack in vivo animal pharmacokinetic (PK) data, given the inability to evaluate models. To address these challenges, this study developed PBK models in the absence of in vivo PK data for the fungicide propiconazole, an activator of constitutive androstane receptor (CAR)/pregnane X receptor (PXR). A fit-for-purpose read-across approach was integrated with hierarchical clustering - an unsupervised machine learning algorithm, to bridge the knowledge gap. The integration allowed the incorporation of a broad spectrum of attributes for analog consideration, and enabled the analog selection in a simple, reproducible, and objective manner. The applicability was evaluated and demonstrated using penconazole (source) and three pseudo-unknown target chemicals (epoxiconazole, tebuconazole and triadimefon). Applying this machine learning-enhanced read-across approach, difenoconazole was selected as the most appropriate analog for propiconazole. A mouse PBK model was developed and evaluated for difenoconazole (source), with the mode of action of CAR/PXR activation incorporated to simulate the in vivo autoinduction of metabolism. The difenoconazole mouse model then served as a template for constructing the propiconazole mouse model. A parallelogram approach was subsequently applied to develop the propiconazole rat and human models, enabling a quantitative assessment of interspecies differences in dosimetry. This integrated approach represents a substantial advancement toward refining risk assessment of propiconazole within the framework of animal alternative safety assessment strategies.
Asunto(s)
Fungicidas Industriales , Aprendizaje Automático , Triazoles , Triazoles/farmacocinética , Animales , Fungicidas Industriales/farmacocinética , Humanos , Medición de Riesgo , Modelos Biológicos , Ratones , CinéticaRESUMEN
Paclobutrazol (PBZ) is a plant growth regulator that can delay plant growth and improve plant resistance and yield. Although it has been widely used in the growth of medicinal plants, human beings may take it by taking traditional Chinese medicine. There are no published studies on PBZ exposure in humans or standardized limits for PBZ in medicinal plants. We measured the solubility, oil-water partition coefficient (logP), and pharmacokinetics of PBZ in rats and established a physiologically based pharmacokinetic (PBPK) model of PBZ in rats. This was followed by extrapolation to healthy Chinese adult males as a theoretical foundation for future risk assessment of PBZ. The results showed that PBZ had low solubility and high fat solubility. Pharmacokinetic experiments showed that PBZ was absorbed rapidly but eliminated slowly in rats. On this basis, the rat PBPK model was successfully constructed and extrapolated to healthy Chinese adult males to predict the plasma concentration-time curve and exposure of PBZ in humans. The construction of the PBPK model of PBZ in this study facilitates the determination of the standard formulation limits and risk assessment of PBZ residues in medicinal plants.
Asunto(s)
Modelos Biológicos , Ratas Sprague-Dawley , Triazoles , Masculino , Animales , Triazoles/farmacocinética , Triazoles/sangre , Humanos , Ratas , Reguladores del Crecimiento de las Plantas/farmacocinética , Adulto , Solubilidad , Medición de RiesgoRESUMEN
OBJECTIVE: Posaconazole (PCZ) is an antifungal drug, which acts by inhibiting the lanosterol-14α-demethylase enzyme. It is a biopharmaceutical classification system class II drug with its bioavailability being limited by poor aqueous solubility. The aim of this study was to improve the oral bioavailability of PCZ by preparing nanocrystalline solid dispersion (NCS). METHODS: PCZ-NCS was prepared by a combination of precipitation and high-pressure homogenization followed by freeze-drying. Several different surfactants and polymers were screened to produce NCS with smaller particle size and higher stability. RESULTS: The optimized NCS formulation containing 0.2% Eudragit S100 and 0.2% SLS was found to provide the average particle size of 73.31 ± 4.7 nm with a polydispersity index of 0.23 ± 0.03. Scanning electron microscopy revealed the preparation of homogeneous and rounded particles. Differential scanning calorimetry and X-ray diffraction confirmed crystalline nature of NCS. Nanonization increased the saturation solubility of PCZ by about 18-fold in comparison with the neat drug. Intrinsic dissolution study showed 93% dissolution of PCZ within the first 10 min. In vivo pharmacokinetic study in Wistar rats showed that Cmax and AUCtotal of PCZ-NCS increased by 2.58- and 2.64-fold compared to the marketed formulation. CONCLUSION: PCZ-NCS formulation presents a viable approach for enhancing the oral bioavailability of PCZ.
Asunto(s)
Antifúngicos , Disponibilidad Biológica , Nanopartículas , Tamaño de la Partícula , Ratas Wistar , Solubilidad , Triazoles , Animales , Nanopartículas/química , Triazoles/farmacocinética , Triazoles/administración & dosificación , Triazoles/química , Antifúngicos/administración & dosificación , Antifúngicos/farmacocinética , Ratas , Masculino , Administración Oral , Composición de Medicamentos/métodos , Liberación de Fármacos , Difracción de Rayos X/métodos , Liofilización , Química Farmacéutica/métodos , Tensoactivos/química , Rastreo Diferencial de Calorimetría/métodosRESUMEN
Trilaciclib is a first-in-class, intravenous cyclin-dependent kinase 4 and 6 inhibitor approved for reducing the incidence of chemotherapy-induced myelosuppression in adult patients with extensive-stage small cell lung cancer receiving a platinum/etoposide-containing or topotecan-containing regimen. No dose adjustment is recommended for participants with mild hepatic impairment (HI) based on previous population pharmacokinetic (PK) analysis. This open-label, parallel-group study examined the impact of moderate and severe HI on the PK of trilaciclib. The study employed a reduced study design. Participants with moderate (Child-Pugh B, n = 8) and severe (Child-Pugh C, n = 5) HI and matched healthy controls (n = 11) received a single intravenous dose of trilaciclib 100 mg/m2. The unbound fraction of trilaciclib was comparable between the HI groups and the matched healthy control group. The unbound trilaciclib extent of exposure (i.e., area under the concentration-time curve) in participants with moderate and severe HI was â¼40% and â¼60% higher, respectively, compared with healthy matched controls based on Child-Pugh classification. Ad hoc analysis using National Cancer Institute classification showed similar results. The US Food and Drug Administration-approved trilaciclib dose of 240 mg/m2 should be reduced by â¼30%, to 170 mg/m2, for patients with moderate or severe HI.
Asunto(s)
Antineoplásicos , Humanos , Masculino , Femenino , Persona de Mediana Edad , Anciano , Antineoplásicos/farmacocinética , Antineoplásicos/efectos adversos , Antineoplásicos/administración & dosificación , Triazoles/farmacocinética , Triazoles/administración & dosificación , Hepatopatías/metabolismo , Inhibidores de Proteínas Quinasas/farmacocinética , Inhibidores de Proteínas Quinasas/administración & dosificación , Lactonas/farmacocinética , Lactonas/administración & dosificación , Adulto , Área Bajo la Curva , Neoplasias Pulmonares/tratamiento farmacológico , Pirimidinas , PirrolesRESUMEN
OBJECTIVES: Posaconazole is increasingly used for the treatment and prophylaxis of invasive fungal infections in immunocompromised children. We aimed to review evidence for paediatric posaconazole dosing regimens focusing on attainment of target concentrations and frequency of adverse effects. METHODS: In May 2023, the Cochrane, Embase, MEDLINE and PubMed databases were searched for articles reporting posaconazole dosing in children with malignancy or post-haematopoietic stem cell transplantation. Studies reporting the attainment of target serum concentrations were included. RESULTS: Overall, 24 studies were included. Eighteen studies of the oral suspension consistently reported poor attainment of target concentrations for prophylaxis (≥0.7â µg/mL, 12%-78%) despite high daily doses of 14-23â mg/kg/day (max. 1200â mg/day). Target attainment was significantly affected by gastric pH and food intake. Six studies of the delayed-release tablet (DRT) reported 58%-94% achieved concentrations ≥0.7â µg/mL, with the majority using lower doses of 4-12â mg/kg/day (max. 300â mg/day). Similarly, one study of powder for oral suspension found 67%-100% achieved target concentrations with a dose of 6â mg/kg/day (max. 300â mg/day). As expected, the IV formulation had high attainment of prophylaxis targets (81%-90%) with 6-10â mg/kg/day (max. 400â mg/day). All formulations were well tolerated, and no relationship between adverse effects and posaconazole concentrations was identified. CONCLUSIONS: The required posaconazole dose in immunocompromised children varies depending on the formulation. The IV infusion had the highest attainment of therapeutic concentration followed by the DRT and powder for suspension. By contrast, the oral suspension had low attainment of target concentrations despite higher daily doses.
Asunto(s)
Antifúngicos , Trasplante de Células Madre Hematopoyéticas , Neoplasias , Triazoles , Humanos , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Antifúngicos/administración & dosificación , Antifúngicos/farmacocinética , Antifúngicos/efectos adversos , Niño , Triazoles/administración & dosificación , Triazoles/farmacocinética , Triazoles/efectos adversos , Huésped Inmunocomprometido , Administración Oral , Infecciones Fúngicas Invasoras/prevención & control , Infecciones Fúngicas Invasoras/tratamiento farmacológico , PreescolarAsunto(s)
Antifúngicos , Enfermedad Crítica , Nitrilos , Piridinas , Triazoles , Humanos , Piridinas/farmacocinética , Piridinas/administración & dosificación , Nitrilos/farmacocinética , Nitrilos/administración & dosificación , Nitrilos/farmacología , Triazoles/farmacocinética , Triazoles/administración & dosificación , Triazoles/farmacología , Antifúngicos/farmacocinética , Antifúngicos/administración & dosificación , Antifúngicos/farmacología , Relación Dosis-Respuesta a DrogaRESUMEN
A liquid chromatography - electrospray ionization-mass spectrometry (LC-ESI-MS) method was developed for the quantification of letrozole, a third-generation aromatase inhibitor, and its main carbinol metabolite (CM) in support of murine pharmacokinetic studies. Using polarity switching, simultaneous ESI-MS measurement of letrozole and CM was achieved in positive and negative mode, respectively. The assay procedure involved a one-step protein precipitation and extraction of all analytes from mouse plasma requiring only 5 µL of sample. Separation was optimized on an Accucore aQ column with gradient elution at a flow rate of 0.4 mL/min in 5 min. Two calibration curves per day over four consecutive measurement days showed satisfactory linear responses (r2 > 0.99) over concentration ranges of 5-1000 ng/mL and 20-2000 ng/mL for letrozole and CM, respectively. No matrix effect was found, and the mean extraction recoveries were 103-108 % for letrozole and 99.8-107 % for CM. Precision and accuracy within a single run and over four consecutive measurement days were verified to be within acceptable limits. Application of the developed method to preclinical pharmacokinetic studies in mice receiving oral letrozole at a dose 1 or 10 mg/kg revealed that the systemic exposure to letrozole was dose-, formulation-, and strain-dependent. These findings may inform the future design of preclinical studies aimed at refining the pharmacological profile of this clinically important drug.
Asunto(s)
Inhibidores de la Aromatasa , Letrozol , Nitrilos , Espectrometría de Masas en Tándem , Triazoles , Animales , Letrozol/sangre , Letrozol/farmacocinética , Letrozol/química , Ratones , Espectrometría de Masas en Tándem/métodos , Inhibidores de la Aromatasa/sangre , Inhibidores de la Aromatasa/farmacocinética , Inhibidores de la Aromatasa/química , Cromatografía Líquida de Alta Presión/métodos , Nitrilos/sangre , Nitrilos/farmacocinética , Triazoles/sangre , Triazoles/farmacocinética , Triazoles/química , Reproducibilidad de los Resultados , Modelos Lineales , Límite de Detección , Femenino , MasculinoRESUMEN
NNRTI is an important component of the highly active antiretroviral therapy (HAART), but the rapid emergence of drug resistance and poor pharmacokinetics limited their clinical application. Herein, a series of novel aryl triazolone dihydropyridines (ATDPs) were designed by structure-guided design with the aim of improving drug resistance profiles and pharmacokinetic profiles. Compound 10n (EC50 = 0.009-17.7 µM) exhibited the most active potency, being superior to or comparable to that of doravirine (DOR) against the whole tested viral panel. Molecular docking was performed to clarify the reason for its higher resistance profiles. Moreover, 10n demonstrated excellent pharmacokinetic profile (T1/2 = 5.09 h, F = 108.96%) compared that of DOR (T1/2 = 4.4 h, F = 57%). Additionally, 10n was also verified to have no in vivo acute or subacute toxicity (LD50 > 2000 mg/kg), suggesting that 10n is worth further investigation as a novel oral NNRTIs for HIV-1 therapy.
Asunto(s)
Fármacos Anti-VIH , Dihidropiridinas , VIH-1 , Simulación del Acoplamiento Molecular , Inhibidores de la Transcriptasa Inversa , Triazoles , VIH-1/efectos de los fármacos , Triazoles/química , Triazoles/farmacología , Triazoles/farmacocinética , Humanos , Fármacos Anti-VIH/farmacología , Fármacos Anti-VIH/química , Fármacos Anti-VIH/síntesis química , Fármacos Anti-VIH/farmacocinética , Inhibidores de la Transcriptasa Inversa/farmacología , Inhibidores de la Transcriptasa Inversa/química , Inhibidores de la Transcriptasa Inversa/síntesis química , Inhibidores de la Transcriptasa Inversa/farmacocinética , Dihidropiridinas/química , Dihidropiridinas/farmacología , Dihidropiridinas/farmacocinética , Relación Estructura-Actividad , Transcriptasa Inversa del VIH/antagonistas & inhibidores , Transcriptasa Inversa del VIH/metabolismo , Animales , Masculino , Descubrimiento de Drogas , Estructura Molecular , RatonesRESUMEN
BACKGROUND: Invasive aspergillosis is a severe fungal infection that affects multiple organ systems including the CNS and the lungs. Isavuconazole, a novel triazole antifungal agent, has demonstrated promising activity against Aspergillus spp. However, data on the penetration of isavuconazole into the CNS and ELF and intracellular accumulation remain limited. MATERIALS AND METHODS: We conducted a prospective single-centre pharmacokinetic (PK) study in 12 healthy volunteers. Subjects received seven doses of 200 mg isavuconazole to achieve an assumed steady-state. After the first and final infusion, plasma sampling was conducted over 8 and 12 h, respectively. All subjects underwent one lumbar puncture and bronchoalveolar lavage, at either 2, 6 or 12 h post-infusion of the final dose. PBMCs were collected in six subjects from blood to determine intracellular isavuconazole concentrations at 6, 8 or 12 h. The AUC/MIC was calculated for an MIC value of 1 mg/L, which marks the EUCAST susceptibility breakpoint for Aspergillus fumigatus and Aspergillus flavus. RESULTS: C max and AUC0-24h of isavuconazole in plasma under assumed steady-state conditions were 6.57â±â1.68 mg/L (meanâ±âSD) and 106â±â32.1 h·mg/L, respectively. The average concentrations measured in CSF, ELF and in PBMCs were 0.07â±â0.03, 0.94â±â0.46 and 27.1â±â17.8 mg/L, respectively. The AUC/MIC in plasma, CSF, ELF and in PBMCs under steady-state conditions were 106â±â32.1, 1.68â±â0.72, 22.6â±â11.0 and 650â±â426 mg·h/L, respectively. CONCLUSION: Isavuconazole demonstrated moderate penetration into ELF, low penetrability into CSF and high accumulation in PBMCs. Current dosing regimens resulted in sufficient plasma exposure in all subjects to treat isolates with MICsâ≤â1 mg/L.
Asunto(s)
Antifúngicos , Voluntarios Sanos , Nitrilos , Piridinas , Triazoles , Humanos , Triazoles/farmacocinética , Triazoles/administración & dosificación , Piridinas/farmacocinética , Piridinas/administración & dosificación , Antifúngicos/farmacocinética , Antifúngicos/administración & dosificación , Masculino , Adulto , Nitrilos/farmacocinética , Nitrilos/administración & dosificación , Estudios Prospectivos , Femenino , Infusiones Intravenosas , Adulto Joven , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Aspergillus fumigatus/efectos de los fármacos , Aspergillus flavus/efectos de los fármacos , Líquido del Lavado Bronquioalveolar/química , Leucocitos Mononucleares/metabolismo , Leucocitos Mononucleares/efectos de los fármacosRESUMEN
BACKGROUND AND OBJECTIVE: Posaconazole is a pharmacotherapeutic pillar for prophylaxis and treatment of invasive fungal diseases. Dose individualization is of utmost importance as achieving adequate antifungal exposure is associated with improved outcome. This study aimed to select and evaluate a model-informed precision dosing strategy for posaconazole. METHODS: Available population pharmacokinetic models for posaconazole administered as a solid oral tablet were extracted from the literature and evaluated using data from a previously published prospective study combined with data collected during routine clinical practice. External evaluation and selection of the most accurate and precise model was based on graphical goodness-of-fit and predictive performance. Measures for bias and imprecision included mean percentage error (MPE) and normalized relative root mean squared error (NRMSE), respectively. Subsequently, the best-performing model was evaluated for its a posteriori fit-for-purpose and its suitability in a limited sampling strategy. RESULTS: Seven posaconazole models were evaluated using 764 posaconazole plasma concentrations from 143 patients. Multiple models showed adequate predictive performance illustrated by acceptable goodness-of-fit and MPE and NRMSE below ± 10% and ± 25%, respectively. In the fit-for-purpose analysis, the selected model showed adequate a posteriori predictive performance. Bias and imprecision were lowest in the presence of two prior measurements. Additionally, this model showed to be useful in a limited sampling strategy as it adequately predicted total posaconazole exposure from one (non-)trough concentration. CONCLUSION: We validated an MIPD strategy for posaconazole for its fit-for-purpose. Thereby, this study is an important first step towards MIPD-supported posaconazole dosage optimization with the goal to improve antifungal treatment in clinical practice.
Asunto(s)
Antifúngicos , Modelos Biológicos , Medicina de Precisión , Triazoles , Humanos , Antifúngicos/administración & dosificación , Antifúngicos/farmacocinética , Triazoles/administración & dosificación , Triazoles/farmacocinética , Triazoles/sangre , Medicina de Precisión/métodos , Masculino , Femenino , Persona de Mediana Edad , Adulto , Administración Oral , Anciano , Estudios Prospectivos , Relación Dosis-Respuesta a Droga , Adulto JovenRESUMEN
BACKGROUND AND OBJECTIVES: Daridorexant, a dual orexin receptor antagonist was recently approved for the treatment of insomnia at doses up to 50 mg once per night. This study investigated the effect of single-dose and multiple-dose daridorexant 50 mg at steady state on the pharmacokinetics (PK) of the cytochrome P450 (CYP) 3A4-sensitive substrate midazolam, and the effect of single-dose daridorexant 50 mg on the PK and pharmacodynamics (PD) of the CYP2C9-sensitive substrate warfarin. METHODS: In this prospective, single-center, open-label, fixed-sequence, phase I, drug-drug interaction study, 18 healthy male subjects sequentially received Treatment A, B, and C in three periods. Treatment A consisted of a single oral concomitant administration of midazolam 2 mg and warfarin 25 mg on day 1 of the first period. Treatment B consisted of one oral administration of daridorexant 50 mg followed 1 h later by a single oral dose of midazolam 2 mg concomitantly with a single oral dose of warfarin 25 mg on day 1 and a once-daily oral administration of daridorexant 50 mg for 6 days of the second period. Treatment C consisted of a single oral administration of daridorexant 50 mg at steady state followed 1 h later by a single oral administration of midazolam 2 mg on day 1 of the third period. Blood samples were assessed for midazolam and S-warfarin PK, and PD (international normalized ratio and factor VII). Noncompartmental PK parameters and PD variables were evaluated with geometric mean ratios and 90% confidence intervals of Treatment B/A versus C/A for midazolam, and treatment B/A for warfarin. Safety and tolerability of each treatment were also assessed. RESULTS: Midazolam maximum plasma concentration (Cmax) and area under the plasma concentration-time curve from 0 to 24 h (AUC0-24) were 1.13- and 1.42-fold higher, respectively, after single-dose administration of daridorexant 50 mg compared to administration of midazolam alone, while Cmax and AUC0-24 were 1.12- and 1.35-fold higher, respectively, after administration of daridorexant 50 mg once daily at steady state. Terminal half-life and time to maximum plasma concentration were comparable between treatments. Daridorexant had no influence on the PK and PD of warfarin. All treatments were safe and well tolerated. CONCLUSIONS: Daridorexant at 50 mg is classified as a weak CYP3A4 inhibitor after single- and multiple-dose administration once daily at steady state. Daridorexant 50 mg did not induce CYP3A4 activity or inhibit CYP2C9 activity. CLINICAL TRIAL REGISTRATION: This trial (NCT05480488) was registered on 29 July, 2022.
Asunto(s)
Interacciones Farmacológicas , Imidazoles , Midazolam , Pirrolidinas , Warfarina , Humanos , Masculino , Midazolam/farmacocinética , Midazolam/administración & dosificación , Adulto , Warfarina/farmacocinética , Warfarina/administración & dosificación , Warfarina/farmacología , Adulto Joven , Voluntarios Sanos , Triazoles/farmacocinética , Triazoles/administración & dosificación , Triazoles/farmacología , Estudios Prospectivos , Antagonistas de los Receptores de Orexina/farmacocinética , Antagonistas de los Receptores de Orexina/farmacología , Antagonistas de los Receptores de Orexina/administración & dosificación , Área Bajo la CurvaRESUMEN
As the first-in-class, selective, and potent inhibitor of the isocitrate dehydrogenase-2 (IDH2) mutant protein, enasidenib was approved by the US Food and Drug Administration (FDA) in 2017 for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an IDH2 mutation. Known for its interactions with various cytochrome P450 (CYP) enzymes and transporters in vitro, a clinical pharmacokinetics (PK) trial was initiated to assess the impact of multiple doses of enasidenib on the single-dose PK of sensitive probe substrates of several cytochrome P450 enzymes and transporters. In this study, a population pharmacokinetic analysis approach was employed to address challenges posed by high, nonzero baseline caffeine concentrations. Moreover, we integrated full Bayesian inference into this approach innovatively for a more detailed understanding of parameter uncertainty and greater modeling flexibility, alongside Student's t-distribution for robust error modeling in handling the abnormal outlier caffeine concentration data observed in this trial. Our analyses demonstrated that multiple doses of enasidenib altered caffeine clearance to a clinically meaningful extent, as evidenced by an approximate 8-fold decrease. This finding led to a specific recommendation in the package insert to avoid the concurrent use of certain CYP1A2 substrates with enasidenib, unless directed otherwise in the prescribing information. Furthermore, this research underlines the technical benefits of integrating full Bayesian inference and incorporating Student's t-distribution for residual error modeling in the PK field.
Asunto(s)
Aminopiridinas , Teorema de Bayes , Cafeína , Interacciones Farmacológicas , Leucemia Mieloide Aguda , Humanos , Leucemia Mieloide Aguda/tratamiento farmacológico , Cafeína/farmacocinética , Cafeína/administración & dosificación , Masculino , Persona de Mediana Edad , Anciano , Femenino , Aminopiridinas/farmacocinética , Aminopiridinas/uso terapéutico , Síndromes Mielodisplásicos/tratamiento farmacológico , Triazoles/farmacocinética , Triazoles/uso terapéutico , Triazoles/sangre , Triazoles/administración & dosificación , Adulto , Modelos Biológicos , Antineoplásicos/farmacocinética , Antineoplásicos/sangre , Antineoplásicos/uso terapéutico , Isocitrato Deshidrogenasa/genética , Isocitrato Deshidrogenasa/antagonistas & inhibidores , TriazinasRESUMEN
Deferasirox is an iron-chelating drug developed by Novartis company for treatment of diseases accompanied by chronic iron overload; such as ß-thalassemia or sickle cell diseases. Owing to its advantages such as high affinity, specificity and wide therapeutic window, it is considered as first line treatment. The current chapter describes the physicochemical characteristics, mode of action, pharmacokinetics, therapeutic applications and synthetic methods for deferasirox. Moreover, it includes Fourier transform infrared spectrometry (FTIR) and nuclear magnetic resonance spectroscopy (NMR) analysis for its functional groups. In addition, the selected analytical methods are summarized to aid the analysts in their routine analysis of deferasirox.
Asunto(s)
Benzoatos , Sobrecarga de Hierro , Humanos , Deferasirox/farmacología , Deferasirox/uso terapéutico , Benzoatos/farmacología , Benzoatos/uso terapéutico , Benzoatos/metabolismo , Triazoles/uso terapéutico , Triazoles/farmacocinética , Quelantes del Hierro/farmacología , Quelantes del Hierro/uso terapéutico , Quelantes del Hierro/metabolismo , Sobrecarga de Hierro/tratamiento farmacológico , Hierro/metabolismo , Hierro/uso terapéuticoRESUMEN
BACKGROUND: Ivosidenib is primarily metabolized by CYP3A4; however, it induces CYP450 isozymes, including CYP3A4 and CYP2C9, whereas it inhibits drug transporters, including P-glycoprotein. Patients with acute myeloid leukemia are at risk of invasive fungal infections, and therefore posaconazole and voriconazole are commonly used in this population. Voriconazole is a substrate of CYP2C9, CYP2C19, and CYP3A4; therefore, concomitant ivosidenib may result in decreased serum concentrations. Although posaconazole is a substrate of P-glycoprotein, it is metabolized primarily via UDP glucuronidation; thus, the impact of ivosidenib on posaconazole exposure is unknown. METHODS: Patients treated with ivosidenib and concomitant triazole with at least one serum trough level were included. Subtherapeutic levels were defined as posaconazole <700 ng/mL and voriconazole <1.0 µg/mL. The incidences of breakthrough invasive fungal infections and QTc prolongation were identified at least 5 days after initiation of ivosidenib with concomitant triazole. RESULTS: Seventy-eight serum triazole levels from 31 patients receiving ivosidenib-containing therapy and concomitant triazole were evaluated. Of the 78 concomitant levels, 47 (60%) were subtherapeutic (posaconazole: n = 20 of 43 [47%]; voriconazole: n = 27 of 35 [77%]). Compared to levels drawn while patients were off ivosidenib, median triazole serum levels during concomitant ivosidenib were significantly reduced. There was no apparent increase in incidence of grade 3 QTc prolongation with concomitant azole antifungal and ivosidenib 500 mg daily. CONCLUSIONS: This study demonstrated that concomitant ivosidenib significantly reduced posaconazole and voriconazole levels. Voriconazole should be avoided, empiric high-dose posaconazole (>300 mg/day) may be considered, and therapeutic drug monitoring is recommended in all patients receiving concomitant ivosidenib.
Asunto(s)
Glicina , Leucemia Mieloide Aguda , Síndromes Mielodisplásicos , Piridinas , Triazoles , Humanos , Leucemia Mieloide Aguda/tratamiento farmacológico , Triazoles/administración & dosificación , Triazoles/uso terapéutico , Triazoles/farmacocinética , Masculino , Femenino , Persona de Mediana Edad , Anciano , Síndromes Mielodisplásicos/tratamiento farmacológico , Piridinas/administración & dosificación , Piridinas/uso terapéutico , Piridinas/farmacocinética , Glicina/análogos & derivados , Glicina/uso terapéutico , Glicina/administración & dosificación , Voriconazol/uso terapéutico , Voriconazol/administración & dosificación , Anciano de 80 o más Años , Interacciones Farmacológicas , Adulto , Antifúngicos/administración & dosificación , Antifúngicos/uso terapéutico , Antineoplásicos/efectos adversosRESUMEN
Lumacaftor/ivacaftor (Orkambi®, LUM/IVA) is indicated for the treatment of cystic fibrosis (CF) patients aged ≥ 2 years with homozygous F580del mutation in the CFTR gene. Triazole fungal agents are used to treat fungal disease in CF. The use of triazoles is limited by pharmacokinetic challenges, such as drug-drug interactions. The most notable drug-drug interaction between triazoles and LUM/IVA is due to strong induction of CYP3A4 and UGT by LUM. In this real-world retrospective observational study, we described the effect of LUM/IVA on the trough concentration of triazoles. Concomitant use of LUM/IVA with itraconazole, posaconazole or voriconazole resulted in subtherapeutic triazole levels in 76% of the plasma samples. In comparison, in patients with triazole agents without LUM/IVA only 30.6% of the plasma samples resulted in subtherapeutic concentrations. Subtherapeutic plasma concentrations of triazoles should be considered in CF patients on LUM/IVA and further research is warranted for other dosing strategies and alternative antifungal therapy.